This site is intended for health professionals only

Bevacizumab can pose thromboembolism risk

teaser

Combination treatment with bevacizumab and chemotherapy, compared with chemotherapy alone, is associated with an increased risk of arterial but not venous thromboembolism, a study has found.

The findings come from a post hoc analyses of data from five randomised controlled trials that included a total of 1,745 patients with metastatic colorectal, breast, or non-small-cell lung carcinoma. The following results were reported:

• Combined treatment with bevacizumab and chemotherapy vs chemotherapy alone was associated with increased risk of arterial thromboembolic event (hazard ratio 2.0, 95% CI 1.05–3.75; p=0.031) but not for a venous thromboembolic event (HR 0.89, 95% CI 0.66–1.20; p=0.44).

• Absolute rate of developing an arterial thromboembolism was 5.5 events per 100 person-years for combination therapy and 3.1 events per 100 person-years for the chemotherapy-alone group (HR 1.8, 95% CI 0.94–3.33; p=0.076).

• Development of an arterial thromboembolic event was associated with a prior arterial thromboembolic event (p<0.001) or age 65 years or older (p=0.01).

• Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events in both treatment groups, from 3.6% to 4.7% for bevacizumab-treated patients and from 1.7% to 2.2% for control subjects.

J Natl Cancer Inst 2007;99:1232-9

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x